NCT06704269 - Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 22, 2025

Primary Completion Date

August 2, 2029

Study Completion Date

October 26, 2029

Conditions

Generalized Myasthenia Gravis

Interventions

GENETIC

YTB323

CAR-T cell suspension for intravenous infusion

Trial Locations (8)

RECRUITING

Novartis Investigative Site, Brest

RECRUITING

Novartis Investigative Site, Bordeaux

RECRUITING

Novartis Investigative Site, Lille

RECRUITING

Houston Methodist Hospital, Houston

RECRUITING

Univ Cali Irvine ALS Neuromuscular, Orange

RECRUITING

Novartis Investigative Site, Chiba

RECRUITING

Wake Forest Univ School of Medicine, Winston-Salem

RECRUITING

Novartis Investigative Site, Kyoto